**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 20486**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

**Dimethyl sulfoxide inhibits zymosan-induced intestinal inflammation and barrier dysfunction**

Li YM *et al*. DMSO inhibits zymosan-induced intestinal inflammation and barrier dysfunction

Yu-Meng Li, Hai-Bin Wang, Jin-Guang Zheng, Xiao-Dong Bai, Zeng-Kai Zhao, Jing-Yuan Li, Sen Hu

**Yu-Meng Li, Jin-Guang Zheng, Zeng-Kai Zhao, Jing-Yuan Li, Sen Hu,** Laboratory for Shock and Multiple Organ Dysfunction of Burns Institute, Key Research Laboratory of Tissue Repair and Regeneration of PLA, and Beijing Key Research Laboratory of Skin Injury and Repair Regeneration, the First Hospital Affiliated to the Chinese PLA General Hospital, Beijing 100048, China

**Yu-Meng Li, Zeng-Kai Zhao,** Medical School of Chinese PLA, Beijing 100853, China

**Hai-Bin Wang,** Department of Clinical Laboratory, The First Hospital Affiliated to the Chinese PLA General Hospital, Beijing 100048, China

**Jin-Guang Zheng, Xiao-Dong Bai,** Department of Burn Surgery, the General Hospital of Armed Police Forces, Beijing 100039, China

**Author contributions:** Li YM and Wang HB contributed equally to this study; Hu S, Li YM, Zheng JG, Wang HB and Bai xd designed the research; Li YM, Zheng JG, Wang HB, Zhao ZK and Li JY performed the research; Hu S, Li YM and Zheng JG analyzed the data; Li YM, Hu S, Wang HB and Bai xd prepared and revised manuscript; all authors have read and approved the final manuscript.

**Supported by** National 11th Five-Year Plan of China for Military Medical Projects, No. 06Z055; and National Basic Research Program of China.

**Institutional review board statement:** The study was reviewed and approved by the First Hospital Affiliated to the Chinese PLA General Hospital Institutional Review Board.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the First Hospital Affiliated to the Chinese PLA General Hospital (IACUC protocol number: [11401500004432]). The experiments were conducted in compliance with the Guide for Care and Use of Laboratory Animals of the National Research Council, China.

**Conflict-of-interest statement:** All authors of this paper have read this manuscript; and no conflicts of interest exist in this study.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at [bs0425@163.com]. Participants gave informed consent for data sharing. Besides, no additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Sen Hu, MD, PhD, Professor,** Laboratory for Shock and Multiple Organ Dysfunction of Burns Institute, Key Research Laboratory of Tissue Repair and Regeneration of PLA, and Beijing Key Research Laboratory of Skin Injury and Repair Regeneration, the First Hospital Affiliated to the Chinese PLA General Hospital, No. 51 Fu Cheng Road, Beijing 100048, China.[bs0425@163.com](mailto:bs0425@163.com)

**Telephone:** +86-10-66867397

**Fax:** +86-10-68989139

**Received:** June 7, 2015

**Peer-review started:** June 8, 2015

**First decision:** July 10, 2015

**Revised:** July 25, 2015

**Accepted:** August 30, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate whether dimethyl sulfoxide (DMSO) inhibits gut inflammation and barrier dysfunction following zymosan-induced systemic inflammatory response syndrome and multiple organ dysfunction syndrome.

**METHODS:** Sprague-Dawley rats were randomly divided into four groups: sham with administration of normal saline (SS group); sham with administration of DMSO (SD group); zymosan with administration of normal saline (ZS group); and zymosan with administration of DMSO (ZD group). Each group contained three subgroups according to 4 h, 8 h and 24 h after surgery. At 4 h, 8 h and 24 h after intraperitoneal injection of zymosan (750 mg/kg), the levels of intestinal inflammatory cytokines (tumor necrosis factor-α and interleukin-10), and oxide (myeloperoxidase, malonaldehyde, and superoxide dismutase) were examined. The levlel of diamine oxidase (DAO) in plasma and intestinal mucosal blood flow (IMBF) were determined. Intestinal injury was also evaluated using an intestinal histological score and apoptosis of intestinal epithelial cells was determined by TUNEL staining. The intestinal epithelial tight junction protein, ZO-1, was observed by immunofluorescence.

**RESULTS:** DMSO decreased tumor necrosis factor-α and increased interleukin (IL)-10 levels in the intestine compared with the ZS group at the corresponding time points. The activity of intestinal myeloperoxidase in the ZS group was higher than that in the ZD group 24 h after zymosan administration (*P* < 0.05). DMSO decreased the content of MDA and increased the activity of SOD 24 h after zymosan administration. The IMBF was lowest at 24 h, and was 49.34% and 58.26% in the ZS group and ZD group, respectively (*P* < 0.05). DMSO alleviated injury in intestinal villi and the gut injury score was significantly lower than that in the ZS group (3.6 ± 0.17 *vs* 4.2 ± 0.29, *P* < 0.05). DMSO decreased the level of DAO in plasma compared with the ZS group (65.1 ± 4.7 U/L *vs* 81.1 ± 5.0 U/L, *P* < 0.05). DMSO significantly preserved ZO-1 protein expression and localization 24 h after zymosan administration. The TUNEL analysis indicated that the number of apoptotic intestinal cells in the ZS group was much higher than that in the ZD group (*P* < 0.05).

**CONCLUSION:**DMSO can inhibit intestinal cytokines and protect against zymosan-induced gut barrier dysfunction.

**Key words:**dimethyl sulfoxide; Zymosan; Inflammation; Intestinal barrier; Tight junction

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We examined whether the administration of dimethyl sulfoxide (DMSO) inhibited zymosan-induced intestinal inflammation and barrier dysfunction to provide an experimental basis for the use of DMSO in protecting intestinal barrier function. We found that DMSO can inhibit intestinal cytokines and protect against zymosan-induced gut barrier dysfunction.

Li YM, Wang HB, Zheng JG, Bai XD, Zhao ZK, Li JY, Hu S. Dimethyl sulfoxide inhibits zymosan-induced intestinal inflammation and barrier dysfunction. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

A large number of bacteria and viruses is found in the human intestine, and the intestinal mucosal barrier is the most important defense mechanism in the body. Intestinal mucosal barrier integrity can separate the luminal content from the body, and prevent intestinal bacteria and endotoxin translocation. The intestinal mucosal barrier is composed of a mechanical barrier, immune barrier, biologic barrier and chemical barrier. A decline in intestinal mucosal barrier function allows luminal bacteria, toxins and other macromolecules such as antigens into the body, which is a key initiation factor in intestinal inflammation and deterioration. Increased permeability exposes the mucosal immune system in the intestinal lumen to foods and bacterial antigens, which stimulate the immune system leading to the occurrence of gut inflammation.

A growing body of evidence indicates that intestinal ischemia plays a critical role in the development of excessive inflammatory-induced organ dysfunction[1,2]. When intestinal permeability and tight junction proteins are damaged, the gut becomes a source of pro-inflammatory mediators, which may amplify systemic inflammatory response syndrome (SIRS), and induce a septic state and distant organ failure. Moreover, it can lead to multiple organ dysfunction syndrome (MODS) and even death[3-5]. In the pathogenesis of MODS induced by an uncontrolled systemic inflammatory response, the intestine is the first organ to be affected and is one of the most easily damaged organs in the pathological process.

Research shows that when the intestine is ischemic, infected or inflamed, bacteria and their toxins can rapidly activate originally static functions of intestinal innate macrophages to produce large amounts of pro-inflammatory cytokines, and these pro-inflammatory factors cause further aggregation of monocytes and polymorphonuclear leukocytes in the intestinal microcirculation and intestinal tissue and release more inflammatory cytokines, oxygen free radicals and inhibit gastrointestinal motility medium[1,6]. This response causes excessive inflammation of the intestine, mucosal edema, intestinal barrier dysfunction and intestinal paralysis, triggering intestinal bacteria and endotoxin translocation and gut-derived sepsis and MODS. Thus, effectively inhibiting the production of intestinal pro-inflammatory cytokines and reducing the production of inflammatory cytokines and oxygen free radicals to protect intestinal tissue from excessive inflammatory damage is significantly important. However, available drugs to protect gut barrier function due to excessive inflammatory response are limited.

Dimethyl sulfoxide (DMSO), a hydrophile-lipophile molecule, has anti-inflammatory, analgesic, diuretic and vasodilatation activity, improves the microcirculation, and affects platelet aggregation hypertonicity[7].Due to its anti-inflammatory properties, DMSO has also been evaluated in the treatment of inflammatory diseases such as cystitis and arthritis[8].In addition, DMSO has been approved by the United States Food and Drug Administration for the treatment of interstitial cystitis by bladder instillation[9,10].Therefore, this study aimed to examine whether the administration of DMSO inhibited zymosan-induced intestinal inflammation and barrier dysfunction and to provide an experimental basis for the use of DMSO in protecting intestinal barrier function.

**MATERIALS AND METHODS**

***Animals***

Male Sprague-Dawley rats (8-10 wk, 251.5 ± 8.7 g) were purchased from the Experimental Animal Center of Military Medical Sciences of the Chinese PLA. The rats were housed in mesh cages in a room maintained at 25°C, illuminated by a 12:12-h light-dark cycle, and provided with standard rodent chow and water ad libitum. The rats were fasted overnight and allowed free access to water up to 4 h before surgery. The Committee of Scientific Research of the First Hospital Affiliated to the Chinese PLA General Hospital, China approved all the research protocols. The experiments were conducted in compliance with the Guide for Care and Use of Laboratory Animals of the National Research Council, China.

***Animal model***

After sterilization of the abdomen, an intraperitoneal injection of high-dose zymosan (750 mg/kg) was administered followed by a subcutaneous injection of DMSO (3 mL/kg, diluted in saline 1:2) or normal saline (3 mL/kg) 1 h after zymosan administration. The animals were allowed to breathe spontaneously under a nose cone scavenging system, using a veterinary anesthesia delivery system (Kent Scientific TOPO, Torrington, CT, United States). Rectal temperature was maintained at 37 °C with a heating pad and a heating lamp. Following the injection of zymosan, the animals developed acute peritonitis. The rats were very ill during the first day, as shown by ruffled fur, skin folds, lethargy, diarrhea, high body temperature and decreased body weight[11].

***Zymosan preparation***

Zymosan (Sigma Chemical, St. Louis, MO, United States) was accurately weighed and the appropriate volume of sterile saline was added to produce a zymosan suspension of 60 mg/mL. A high frequency magnetic stirrer was used to stir the suspension until blended. Disinfection was carried out in a 100 °C water bath for 80 min, and the suspension was then cooled to room temperature. The suspension was heated to 40 °C and high-frequency vibration blending was performed before use. The zymosan suspension was then injected intraperitoneally at the dose of 750 mg/kg.

***Animal grouping and treatment***

All the animals underwent the same procedure, and were then randomly divided into four groups, weighed and scored. In the ZS group and ZD group, an intraperitoneal injection of high-dose zymosan (750 mg/kg) was administered followed by a subcutaneous injection of DMSO (3 mL/kg, diluted in saline 1:2) in the ZD group and normal saline (3 mL/kg) in the ZS group 1 h after zymosan administration. In the SS group and SD group, an intraperitoneal injection of normal saline was administered in each group and then 1 h later a subcutaneous injection of DMSO (3 mL/kg, diluted in saline 1:2) was administered in the ZD group and normal saline (3 mL/kg) in the ZS group. The SS group and SD group were treated as the surgery and drug controls, respectively. Each group was divided into three subgroups according to 4 h, 8 h and 24 h after injury. In total, there are 12 subgroups , because there are four groups, and each group has three time points. Eight samples were needed from each subgroup. According to the model of a 50% mortality rate at 24 h, each subgroup consisted of 16-20 rats. Then 8 animals from each subgroup were randomly selected from the surviving rats for the eight samples.

***Blood and intestine samples***

The rats were anesthetized by inhalation of 3% isoflurane (Yeeran Technology Limited, Beijing, China), the aorta was punctured and exsanguinated at 4 h, 8 h and 24 h after surgery. For DAO , blood was collected, and plasma was obtained by centrifuging the blood at 10000 × *g* for 10 min at 4 °C. The animals were then sacrificed and the distal small intestine was harvested. Segments of the distal small intestine were harvested and fixed in 4% paraformaldehyde for histologic evaluation, TUNEL analysis and immunofluorescent staining. Segments of the distal small intestine were removed, snap-frozen in liquid nitrogen and stored at -80 °C for Western blot and ELISA. Segments of the distal small intestine stored at -40 °C for the inflammatory cytokines.

***Determination of TNF-α and IL-10 levels in intestine***

Intestine tissue (100 mg) in 1 ml phosphate-buffered saline (PBS) was homogenized at 4 °C with a Polytron homogenizer. After centrifugation at 10000 g at 4 °C for 10 min, the supernatants were collected. TNF-a and IL-10 in the intestine supernatants was quantified with a commercial ELISA kit (Nanjing Jiancheng Corp., China) according to the manufacturer’s instructions. Intestinal TNF-α and IL-10 levels were expressed as picograms per milligram of protein.

***Determination of intestinal tissue myeloperoxidase activity***

Intestinal tissue myeloperoxidase (MPO) activity was determined using a kit according to the manufacturer’s instructions. The tissue homogenate and reagent were placed in a water bath at 60 °C for 10 min after being thoroughly mixed. The absorbance value of each tube was then determined at 460 nm immediately after removal from the water bath. The activity of MPO in the intestine was calculated according to the following formula: MPO (U/weight grams) = (determination OD value - control OD value) / 11.3 x sample volume (g).

***Determination of******malonaldehyde content in intestine***

Intestinal malonaldehyde (MDA) was determined using a kit according to the manufacturer’s instructions. The tissue homogenate and reagent were placed in a water bath at 95 °C for 40 min after being thoroughly mixed. After cooling, the mixture was centrifuged at 4000 r/m for 10 min. The absorbance value of each supernatant was then determined at 532 nm immediately after removal from the water bath. The content of MDA in the intestine was calculated according to the following formula: MDA (nmol/mgProt）= [(determination tube absorbance - blank tube absorbance) / (standard tube absorbance - blank tube absorbance)] x standard concentrations÷protein content.

***Determination of superoxide dismutase activity in intestine***

Intestinal superoxide dismutase (SOD) activity was determined using a kit according to the manufacturer’s instructions. The tissue homogenate and reagent were placed in a water bath at 37 °Cfor 40 min after being thoroughly mixed. After 10 min at room temperature, the absorbance value of each supernatant was determined at 550 nm. The activity of SOD in the intestine was calculated according to the following formula: SOD (U.mL-1) = [(control tube absorbance - determination tube absorbance)/control tube absorbance] ÷ 50% × reaction system dilution multiple × sample dilution multiple.

***Measurement of intestinal mucosal blood flow***

A laser Doppler flowmeter (Perimed AB; Stockholm, Sweden) was used to monitor intestinal mucosal blood flow (IMBF)at 4 h, 8 h and 24 h after surgery. The probe of the blood flow meter was aimed at the proximal jejunum and the laser was focused on the mesentery. The flow signal was measured for 30 s, and a 10-s stable signal was selected to calculate the mean value expressed in the blood perfusion unit (BPU).

***Histopathologic score***

Segments of the distal ileum were fixed in 4% paraformaldehyde for 48 h, embedded in paraffin, and sectioned. Hematoxylin and eosin staining of the intestine was performed after deparaffinization and rehydration. Two pathologists who were blinded to the experimental groups, then viewed and evaluated the sections under a light microscope. Three randomly selected fields from each specimen were graded using a scoring system which characterized gut injury on a scale of 0 to 4 developed by Chiu *et al*[12].

***Intestinal epithelial permeability***

Determination of DAO activity was performed to assess gut barrier function. The activity of DAO was evaluated using an assay kit (Jiancheng Biotech Ltd., Nanjing, China) according to the manufacturer’s instructions.

***Immunofluorescence***

After deparaffinization, the intestine sections were rehydrated and incubated in citrate buffer (Zhongshan Jinqiao Biotechnology Co., Ltd., Beijing, China) for heat-induced antigen retrieval. After three washes with PBS, the sections were incubated with 3% BSA (Zhongshan Jinqiao Biotechnology Co., Ltd., Beijing, China) for 30 min to block nonspecific binding sites. The sections were then incubated with the ZO-1 antibody (1:100; Life Technologies, Gaithersburg, MD, United States) at 4 °C overnight. The following day, after washing with PBS three times, they were treated with Alexa Fluor 488 secondary goat anti-rabbit antibody in 1% BSA for 1 h at room temperature followed by 3 washes with PBS and mounted using Antifade Solution (Applygen Technologies Inc., Beijing, China). The negative control incubated with PBS instead of the ZO-1 antibody and other steps are same as above. Images were viewed using an Olympus fluorescence microscope (BX51-DP71) with exposure-matched settings.

***Deoxynucleotidyl transferase dUTP nick end labeling analysis***

Deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis was performed using the In Situ Cell Death Detection kit (Roche Diagnostics GmbH., Penzberg, Germany) according to the manufacturer’s instructions. Segments of the distal ileum were fixed in 4% paraformaldehyde for 48 h, embedded in paraffin, and sectioned. The sections were incubated with pepsin digestion liquid in a wet box for 60 min after deparaffinization and rehydration. After 2 washes, 100 L DNase 1 (1500 U/mL) was added to the positive control group and incubated in a wet box for 20 min. Fifty μL TUNEL reaction mixture solution (50 L enzyme solution + 450 L label solution) was added to the positive control group and the experimental group, and 50 L label solution was added to the negative control group. The sections were incubated in the dark in the wet box for 60 min. Differential interference contrast microscopy images were then obtained at 400 × magnification following the random selection of intestinal mucosa in 5 non-overlapping regions. The number of apoptotic intestinal mucosa cells and total intestinal mucosa cells were counted, and then the cell apoptosis rate was determined by the following equation: cell apoptosis rate = the number of apoptotic cells / total cells × 100%.

***Statistical analysis***

Data were analyzed using a commercial statistical software package (SPSS Statistics 17.0). Continuous variables were expressed as mean ± SE. Statistically significant differences were determined using one way analysis of variance (ANOVA). Dunnett’s test was used to compare within groups and SNK-q analysis was used to compare between groups. If variables were non-normally distributed, the Kruskal-Wallis H test was used. In all tests, a *P* value < 0.05 was considered statistically significant.

**RESULTS**

***Effect of DMSO on intestinal cytokine levels***

Figure 1 illustrates the effect of DMSO on TNF-α and IL-10 levels in rat intestine following intraperitoneal administration of zymosan. Zymosan induced increases in TNF-α and IL-10 in intestinal homogenates. DMSO reduced TNF-α levels and increased IL-10 levels. The TNF-α and IL-10 contents in group ZS and group ZD were significantly higher than those in group SS and group SD (*P* < 0.05) after zymosan administration. The content of TNF-α in group ZD was significantly lower than that in group ZS at 4 h and 8 h (*P* < 0.05), while the IL-10 level in group ZD was higher than that in group ZS at all time points.

***DMSO decreases intestinal MPO activity***

The activity of MPO in group ZS and group ZD was significantly different from that in group SS and group SD. A decrease in MPO in group ZD compared with group ZS was observed at 24 h (*P* < 0.05). This indicated that DMSO reduced the accumulation of neutrophils in the gut (Figure 2).

***DMSO lowers intestinal MDA content and SOD activity***

The MDA content and SOD activity were significantly increased after intraperitoneal injection of zymosan. Both MDA content and SOD activity increased with increasing time and were highest at 24 h. Furthermore, MDA content in group ZD was lower than that in group ZS, and SOD activity was highest at 24 h (*P <* 0.05). This indicated that DMSO decreased MDA content, increased SOD activity, and reduced the damage caused by lipid peroxidation (Figure 3).

***DMSO increases intestinal mucosal blood flow***

IMBF in group SS and group SD was not significantly different at 4 h, 8 h and 24 h. IMBF in group ZS and group ZD was significantly lower than that in group SS and group SD (*P* < 0.05) after zymosan administration. The lowest level in group ZS and group ZD, was 46.29% of that in group SS and 62.21% of that in group SD, respectively, at 24 h. The levels of IMBF in group ZD were significantly higher than those in group ZS at 8 h and 24 h (*P* < 0.05). These results indicated that DMSO improved IMBF and intestinal perfusion (Figure 4).

***DMSO decreases intestinal injury***

Histologic evaluation of intestinal mucosa was performed based on Chiu’s grading system[12]. Histopathologic analysis of the sham group (sham + SS and sham + SD) showed a normal mucosal pattern. The villi were packed, tall, and intact. Compared with the sham group, intraperitoneal injection of zymosan caused significant mucosal damage. The intestinal villi became erosive, hyperemic, edematous, atrophic and the villous stroma was full of inflammatory cells, and epithelial cell villi showed necrosis and exfoliation. These effects increased with time. No significant difference was observed between group ZS and group ZD at 4 h (*P* > 0.05). However, DMSO treatment significantly attenuated mucosal damage at 24 h (*P* < 0.05) (Figures 5 and 6)

.

***DMSO lowers the release of DAO***

The activity of DAO in group SS and group SD was not significantly different. The activity of DAO in group ZS and group ZD was significantly higher than that in group SS and group SD (*P* < 0.05) after zymosan administration. The activity was highest at 24 h in group ZS (81.10 ± 5.01 U/L) and group ZD (65.09 ± 4.74 U/L) and increased to 73.58% and 67.08% of group SS (21.43 ± 3.12 U/L) and group SD (21.43 ± 3.12 U/L), respectively. The activity of DAO in group ZD was significantly lower than that in group ZS (*P* < 0.05) at 8 h and 24 h. These results indicate that DMSO reduced the release of DAO into the bloodstream and protected intestinal structure and function (Figure 7).

***DMSO prevents loss and redistribution of ZO-1***

To assess the effects of DMSO on the expression of ZO-1, a tight junction protein, immunoflourescence was performed. Exposure-matched fluorescent intensity correlated with ZO-1 protein expression after immunostaining. In the sham group, ZO-1 was densely and continuously distributed along the apical membrane of epithelial cells (Figure 8). The expression pattern of ZO-1 was similar in group SS and group SD at all time points. Intraperitoneal administration of zymosan caused a loss of ZO-1 expression at 8 h (Figure 8), and zymosan-induced loss of ZO-1 was more pronounced at 24 h, resulting in a low expression of ZO-1 at the cell periphery (Figure 8). The pattern of ZO-1 expression in group ZS was lower than that in group SS at 8 h and 24 h. Following treatment with DMSO, the loss of ZO-1 was attenuated, and the level of ZO-1 continually improved 8 and 24 h after intraperitoneal administration of zymosan (Figure 8). Intraperitoneal zymosan (ZS group) resulted in a significant reduction in intestinal ZO-1 expression and DMSO treatment (ZD group) attenuated the degradation of ZO-1 at 8 and 24 h.

***DMSO decreases apoptosis in the intestine***

The rate of apoptosis in intestinal tissues in group SS and group SD were not significantly different, and the rate of apoptosis in intestinal cells in group ZS and group ZD was significantly higher than that in the sham control group (all *P <* 0.05). The rate of apoptosis increased with time after zymosan administration. The rate of apoptosis in intestinal tissues in group ZD was significantly lower than that in group ZS (*P* < 0.05) at all time points. These results indicate that DMSO may inhibit intestinal cell apoptosis (Figure 9).

**DISCUSSION**

Multiple organ dysfunction syndrome refers to the clinical syndrome of simultaneous or sequential dysfunction of two or more organs leading to an unstable internal environment after severe trauma, shock and infection[13].Under physiological conditions, the body maintains a balance between pro-inflammatory and anti-inflammatory reactions, as a protective response against foreign invasion. Pro-inflammatory factors initiate and promote inflammation and injury to the body, through the release of "aggressive" inflammatory mediators. Anti-inflammatory cytokines are released by pro-inflammatory cytokines and are involved in defense, and promote anti-inflammatory reactions and tissue repair. However, when the pro-inflammatory or inflammatory reaction is too strong or too weak, the body is in a state of immune hyperfunction or immune suppression, the inflammatory response cannot be controlled and homeostasis is disrupted. Infection, trauma and ischemia reperfusion injury results in the excessive activation of inflammatory cells such as macrophages, neutrophils and endothelial cells with the excessive release of inflammatory mediators. This causes the "waterfall effect", inducing a systemic inflammatory reaction syndrome (SIRS), and if not treated leads to multiple organ dysfunction[14-16]. Therefore, the balance between pro-inflammatory mediators and anti-inflammatory factors determines the prognosis of the disease, and the imbalance between the two types of cytokines is an important cause of further development of SIRS and MODS.

Zymosan is a substance derived from the cell wall of the yeast *Saccharomyces cerevisiae*. Intraperitoneal injection of zymosan in mice or rats leads to systemic inflammation and organ damage, by inducing a wide range of inflammatory mediators of the complement system[17], prostaglandins and leukotrienes[18], platelet aggregation factor[19], oxygen radicals[20], and lysosomal enzymes[21]. In the mid 1980s, the zymosan-induced generalized inflammation (ZIGI) model was first introduced by Goris[22].To date, the ZIGI model is recognized as the best model as it resembles human MODS and has been widely used to study systemic inflammation in relation to organ failure. Cuzzocera[23,24] administered intraperitoneal zymosan to animals, inducing acute peritonitis and multiple organ damage within 18 h. Inflammatory lesions play a role in the process of systemic inflammation and multiple organ damage induced by zymosan. Zymosan induces the excessive release of inflammatory mediators, damages vascular endothelial cells and slows blood flow. Inflammatory cells, and platelets adhere to the endothelium, leukocytes migrate into the gap, release a variety of inflammatory transmitters, and damage the endothelial barrier and tissue.

After intraperitoneal injection of zymosan, pro-inflammatory factors and anti-inflammatory factors in the blood increase significantly, and the uncontrolled synthesis and release of these factors induce SIRS. In recent years, research has shown that DMSO can inhibit the activation of NF-kappa B (NF-Kβ) stimulated by LPS in mouse macrophages[25] and intestinal Caco-2 cells[26], lower mRNA expression of cytokines, and reduce the biological activity of TNF. DMSO inhibits the activation of rat NF-Kβ in sepsis, the expression of ICAM-1 gene and the expression of inflammatory factors such as TNF-α[27]. Following selective inhibition of the NLRP3 inflammatory complex, inhibition of mature IL-1 and casP1, casP1 activity and ASC pyroptosomes, DMSO was further confirmed to have anti-inflammatory effects in animal sepsis and inflammatory bowel disease models[28].

TNF-α is the primary factor in initiation of the cascade of inflammatory cytokines during SIRS, and IL-10 is considered to be the most important anti-inflammatory cytokine *in vivo*. The increase in TNF-α, as a positive feedback to the activation of NF-Kβ, upregulates the expression and release of cytokines such as IL-2 and ICAM-1, and plays a role in causing inflammatory damage to tissues. DMSO reduces the formation of inflammatory mediators, localizes the inflammatory response, and controls the systemic inflammatory response in the appropriate range, preventing the development of SIRS and even MODS. IL-10 inhibits the activity of NF-Kβ in at least two ways: (1) DMSO prevents the dissociation of NF-Kβ and protein IKβ, by inhibiting the activity of IKβ kinase; and (2) DMSO inhibits NF-Kβ combining with the DNA transcriptional regulatory region, thereby inhibiting the transcription of corresponding inflammatory factors[29,30].

In the present study, zymosan induced peritonitis, ascites leakage, and intestinal edema, and significantly reduced intestinal blood flow, decreased the expression of intestinal tight junction protein ZO-1, increased intestinal permeability, which were correlated with the release of pro-inflammatory factors such as TNF-α. After the administration of DMSO, intestinal inflammatory factor TNF-α was significantly decreased, and IL-10, blood flow and expression of ZO-1 were increased, indicating that DMSO decreased the synthesis and release of inflammatory factor TNF-α, and increased the release of IL-10 to alleviate inflammatory damage caused by these factors. Previous studies have shown that macrophage Toll-like receptor 2 combined with zymosan leads to activation of NF-Kβ and generation of the pro-inflammatory factor TNF-α[31,32].In this study, DMSO inhibited the synthesis and release of TNF-α, indicating that DMSO is likely to inhibit the activation of NF-Kβ, and reduce the synthesis and release of TNF-α.

The activity of MPO in tissues, reflects the aggregation of neutrophils at inflammatory sites. After intraperitoneal injection of zymosan, intestinal MPO activity significantly increased with time, demonstrating the aggregation of neutrophils in the intestine. However, the effect of DMSO on neutrophil activity and white blood cell count was not significant, and showed some influence only at 24 h. DMSO may inhibit the oxidative stress reaction mediated by neutrophils to alleviate injury caused by zymosan.

After intraperitoneal injection of zymosan, viscera microcirculation blood flow decreased, the tissue was ischemic and anoxic, and produced a large number of free radicals. Therefore, the animals continued to be in a state of oxidative stress, endogenous antioxidant enzyme activity was reduced and the body's redox system balance was disrupted. MDA is the main metabolite in lipid peroxidation, and its content can reflect the degree of lipid peroxidation and indirectly reflect the degree of oxidative damage[33]. Previous research showed that DMSO can reduce MDA and NO level, inhibit or increase the level of GSH, and alleviate liver injury and ischemia reperfusion-induced transaminase release[34,35]. DMSO can also reduce renal damage caused by HgCl2[36]. In addition, SOD is an important antioxidant enzyme in organisms and the primary enzyme involved in scavenging free radicals. Oxygen free radicals can activate NF-Kβ, thus a reduction in oxidative products and an improvement in antioxidant enzymes decrease the serum and tissue levels of pro-inflammatory cytokines and protect organ function[37]. In this study, intraperitoneal injection of zymosan increased MDA content and SOD activity in the intestine, while subcutaneous injection of DMSO suppressed the increase in MDA and SOD. These results demonstrate that DMSO can reduce the damage caused by visceral lipid peroxidation mediated by oxygen free radicals by scavenging free radicals.

Cell apoptosis regulates body development and maintains a stable internal environment *via* a series of genes that control the process of active cell death. Intestinal mucosal epithelial cell proliferation, differentiation and apoptosis are processes of dynamic change. However, the balance is disrupted in inflammatory bowel disease, where the occurrence and scope of epithelial cell apoptosis is higher than that in normal tissue[38]. Epithelial cell apoptosis is mainly due to activation of the Fas/FasL signal transduction pathway, and both Bcl-2 and Bax[39,40]. In this study, intestinal epithelial cell apoptosis was increased following intraperitoneal administration of zymosan, and was reduced by DMSO, however, the specific mechanism involved in the effect of DMSO requires further study.

In conclusion, DMSO reduced intestinal tissue injury after intraperitoneal injection of zymosan, restored intestinal blood flow, and protected intestinal function. The mechanism likely involves regulation of the balance between pro-inflammatory and anti-inflammatory factors, inhibition of peroxidation in organs, oxygen free radical scavenging, reduction in intestinal epithelial cell apoptosis, and alleviation of intestinal function damage.

**ACKNOWLEDGMENTS**

The authors thank Dr. Jiang-Yang Lu, Yi-Duo Jin, Xiu-Li Ma, Hui-Zhen Ding, Yi Yang and Dong-Mei Yang from the Department of Pathology, First Hospital Affiliated to the PLA General Hospital, for their technical assistance. The authors also thank Hui-Ping Zhang, Ming-Juan Gao and Xiao-Na Zhang for their assistance with the experiments.

**COMMENTS**

***Background***

When severe injury occurs, the blood supply to the intestinal tract is sharply reduced, which results in gut barrier dysfunction. The incidence of serious complications is increased following dysfunction of the gut barrier. This promotes bacterial translocation and the local production of cytokines. Bacteria and their endotoxins move into the circulation and remote organs, contributing to subsequent local and systemic inflammation. This may lead to systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). Therefore, protecting the intestinal barrier function is important. Thus, interventions such as drugs to prevent excessive inflammation and the redox reaction are of great significance in controlling SIRS and MODS induced by zymosan.

***Research frontiers***

The current treatment for SIRS and MODS is limited, therefore, it is important to identify alternative therapies. Dimethyl sulfoxide (DMSO) has been found to have anti-inflammatory, analgesic, diuretic and vasodilatation activities, improves the microcirculation, and effects platelet aggregation hypertonicity. In addition, DMSO has been studied in the treatment of inflammatory diseases such as cystitis and arthritis. DMSO can reduce MDA and NO level, and alleviate liver injury. DMSO can also reduce renal damage caused by HgCl2. However, whether DMSO can protect intestinal function in SIRS and MODS and its specific mechanism are unclear.

***Innovations and breakthroughs***

The most important novel findings in this study are that DMSO inhibits zymosan-induced intestinal inflammation and barrier dysfunction. Regulation of the balance between pro-inflammatory and anti-inflammatory reactions and inhibition of excessive oxidation are considered a possible mechanism of DMSO in regulating zymosan-induced intestinal barrier function.

***Applications***

These study results provide evidence for the possible mechanism of DMSO in regulating intestinal barrier function after zymosan-induced systemic inflammatory response syndrome and multiple organ dysfunction syndrome.

***Terminology***

The intestinal barrier function: refers to the function of the intestine in preventing harmful substances such as bacteria and toxins entering the intestinal mucosa, other organs and the blood circulation. The normal intestinal mucosal barrier is composed of a mechanical barrier, chemical barrier, immunologic barrier and biological barrier. Inflammation of the intestine: Intestinal ischemia, infection and inflammation can activate intestinal inflammatory cells to release many cytokines, oxygen free radicals and inhibit gastrointestinal motility medium, resulting in excessive inflammation, mucosal edema and intestinal barrier damage. DMSO is a hydrophile-lipophile molecule and is widely used as a solvent for biological compounds. It has anti-inflammatory, analgesic, diuretic, and vasodilatation activity, improves the microcirculation, and effects platelet aggregation hypertonicity. Zymosan：zymosan is a substance derived from the cell wall of the yeast *Saccharomyces cerevisiae.* It is composed of polysaccharide chains of various molecular weights, and contains approximately 73% polysaccharides, 15% proteins, and 7% lipids and inorganic components. When injected into animals, it results in inflammation by inducing a wide range of inflammatory mediators.

***Peer-review***

This is a well written and set up study. The authors give a sufficient overview about the study background and raised clearly the hypothesis of the study. The aim of the study is fulfilled. The Results are presented sufficiently well and have been discussed well; the 9 figures give good overview about the results and are presented correctly.

**REFERENCES**

1 **Moore FA**. The role of the gastrointestinal tract in postinjury multiple organ failure. *Am J Surg* 1999; **178**: 449-453 [PMID: 10670850]

2 **Deitch EA**, Xu D, Franko L, Ayala A, Chaudry IH. Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. *Shock* 1994; **1**: 141-145 [PMID: 7749933]

3 **Wang W**, Smail N, Wang P, Chaudry IH. Increased gut permeability after hemorrhage is associated with upregulation of local and systemic IL-6. *J Surg Res* 1998; **79**: 39-46 [PMID: 9735238]

4 **Thuijls G**, de Haan JJ, Derikx JP, Daissormont I, Hadfoune M, Heineman E, Buurman WA. Intestinal cytoskeleton degradation precedes tight junction loss following hemorrhagic shock. *Shock* 2009; **31**: 164-169 [PMID: 18650780 DOI: 10.1097/SHK.0b013e31817fc310]

5 **Fink MP**, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. *Crit Care Clin* 2005; **21**: 177-196 [PMID: 15781156]

6 **Hassoun HT**, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. *Shock* 2001; **15**: 1-10 [PMID: 11198350]

7 **Santos NC**, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. *Biochem Pharmacol* 2003; **65**: 1035-1041 [PMID: 12663039]

8 **Kloesch B**, Liszt M, Broell J, Steiner G. Dimethyl sulphoxide and dimethyl sulphone are potent inhibitors of IL-6 and IL-8 expression in the human chondrocyte cell line C-28/I2. *Life Sci* 2011; **89**: 473-478 [PMID: 21821055 DOI: 10.1016/j.lfs.2011.07.015]

9 **Sant GR**. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. *Urology* 1987; **29**: 17-21 [PMID: 3551281]

10 **Parkin J**, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis--a practical approach. *Urology* 1997; **49**: 105-107 [PMID: 9146010]

11 **Jansen MJ**, Hendriks T, Verhofstad AA, Lange W, Geeraedts LM, Goris RJ. Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. *Shock* 1997; **8**: 261-267 [PMID: 9329127]

12 **Chiu CJ**, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. *Arch Surg* 1970; **101**: 478-483 [PMID: 5457245 DOI: 10.1001/archsurg.1970.01340280030009]

13 **Kramer N**, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. *Am J Respir Crit Care Med* 1995; **151**: 1799-1806 [PMID: 7767523]

14 **Hotchkiss RS**, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; **348**: 138-150 [PMID: 12519925]

15 **Lee WL**, Slutsky AS. Sepsis and endothelial permeability. *N Engl J Med* 2010; **363**: 689-691 [PMID: 20818861 DOI: 10.1056/NEJMcibr1007320]

16 **Hotchkiss RS**, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis* 2013; **13**: 260-268 [PMID: 23427891 DOI: 10.1016/S1473-3099(13)70001-X]

17 **Pillemer L**, Ecker EE. Anticomplementary factor in fresh yeast. *J Biol Chem* 1941; **137**: 139–142

18 **Humes JL**, Sadowski S, Galavage M, Goldenberg M, Subers E, Bonney RJ, Kuehl FA. Evidence for two sources of arachidonic acid for oxidative metabolism by mouse peritoneal macrophages. *J Biol Chem* 1982; **257**: 1591-1594 [PMID: 6799509]

19 **Roubin R**, Mencia-Huerta JM, Landes A, Benveniste J. Biosynthesis of platelet-activating factor (PAF-acether). IV. Impairment of acetyl-transferase activity in thioglycollate-elicited mouse macrophages. *J Immunol* 1982; **129**: 809-813 [PMID: 6806384]

20 **Nauseef WM**, Root RK, Newman SL, Malech HL. Inhibition of zymosan activation of human neutrophil oxidative metabolism by a mouse monoclonal antibody. *Blood* 1983; **62**: 635-644 [PMID: 6309281]

21 **Bonney RJ**, Wightman PD, Davies P, Sadowski SJ, Kuehl FA, Humes JL. Regulation of prostaglandin synthesis and of the selective release of lysosomal hydrolases by mouse peritoneal macrophages. *Biochem J* 1978; **176**: 433-442 [PMID: 743251]

22 **Goris RJ**, Boekholtz WK, van Bebber IP, Nuytinck JK, Schillings PH. Multiple-organ failure and sepsis without bacteria. An experimental model. *Arch Surg* 1986; **121**: 897-901 [PMID: 3729706]

23 **Imperatore F**, Cuzzocrea S, De Lucia D, Sessa M, Rinaldi B, Capuano A, Liguori G, Filippelli A, Rossi F. Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome. *Intensive Care Med* 2006; **32**: 1881-1888 [PMID: 16977483]

24 **Impellizzeri D**, Mazzon E, Di Paola R, Paterniti I, Bramanti P, Cuzzocrea S. Effect of NADPH-oxidase inhibitors in the experimental model of zymosan-induced shock in mice. *Free Radic Res* 2011; **45**: 820-834 [PMID: 21623687 DOI: 10.3109/10715762.2011.581667]

25 **Kelly KA**, Hill MR, Youkhana K, Wanker F, Gimble JM. Dimethyl sulfoxide modulates NF-kappa B and cytokine activation in lipopolysaccharide-treated murine macrophages. *Infect Immun* 1994; **62**: 3122-3128 [PMID: 8039880]

26 **Hollebeeck S**, Raas T, Piront N, Schneider YJ, Toussaint O, Larondelle Y, During A. Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2 cell model. *Toxicol Lett* 2011; **206**: 268-275 [PMID: 21878375 DOI: 10.1016/j.toxlet.2011.08.010]

27 **Chang CK**, Llanes S, Schumer W. Inhibitory effect of dimethyl sulfoxide on nuclear factor-kappa B activation and intercellular adhesion molecule 1 gene expression in septic rats. *J Surg Res* 1999; **82**: 294-299 [PMID: 10090842]

28 **Ahn H**, Kim J, Jeung EB, Lee GS. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. *Immunobiology* 2014; **219**: 315-322 [PMID: 24380723 DOI: 10.1016/j.imbio.2013.11.003]

29 **Schottelius AJ**, Mayo MW, Sartor RB, Baldwin AS. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. *J Biol Chem* 1999; **274**: 31868-31874 [PMID: 10542212]

30 **Driessler F**, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. *Clin Exp Immunol* 2004; **135**: 64-73 [PMID: 14678266]

31 **Frasnelli ME**, Tarussio D, Chobaz-Péclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. *Arthritis Res Ther* 2005; **7**: R370-R379 [PMID: 15743485]

32 **Tian B**, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. *Recent Prog Horm Res* 2003; **58**: 95-130 [PMID: 12795416]

33 **Janero DR**. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. *Free Radic Biol Med* 1990; **9**: 515-540 [PMID: 2079232]

34 **Stein HJ**, Oosthuizen MM, Hinder RA, Lamprechts H. Oxygen free radicals and glutathione in hepatic ischemia/reperfusion injury. *J Surg Res* 1991; **50**: 398-402 [PMID: 2020191]

35 **Akyürek N**, Kafali EM, Muhtaroglu S. The effects of dimethylsulfoxide on experimental hepatic ischemia. *Swiss Surg* 2000; **6**: 23-27 [PMID: 10709433]

36 **Jo SK**, Hu X, Yuen PS, Aslamkhan AG, Pritchard JB, Dear JW, Star RA. Delayed DMSO administration protects the kidney from mercuric chloride-induced injury. *J Am Soc Nephrol* 2004; **15**: 2648-2654 [PMID: 15466269]



37 **Xie K**, Yu Y, Zhang Z, Liu W, Pei Y, Xiong L, Hou L, Wang G. Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model. *Shock* 2010; **34**: 495-501 [PMID: 20351628 DOI: 10.1097/SHK.0b013e3181def9aa]

38 **Iwamoto M**, Koji T, Makiyama K, Kobayashi N, Nakane PK. Apoptosis of crypt epithelial cells in ulcerative colitis. *J Pathol* 1996; **180**: 152-159 [PMID: 8976873]

39 **Martin CA**, Panja A. Cytokine regulation of human intestinal primary epithelial cell susceptibility to Fas-mediated apoptosis. *Am J Physiol Gastrointest Liver Physiol* 2002; **282**: G92-G104 [PMID: 11751162]

40 **Lu J**, Caplan MS, Saraf AP, Li D, Adler L, Liu X, Jilling T. Platelet-activating factor-induced apoptosis is blocked by Bcl-2 in rat intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 2004; **286**: G340-G350 [PMID: 14512286]



**P-Reviewer:** Vorobjova t **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**




**Figure 1 Tumor necrosis factor-α and interleukin-10 levels in rat intestine at 4, 8 and 24 h after intraperitoneal injection of zymosan.** Intestine samples were obtained at 4, 8 and 24 h after intraperitoneal injection of zymosan. Data are expressed as mean ± SD (8 animals per group at each time point). a*P* < 0.05 *vs* group SS and group SD; b*P* < 0.05 *vs* groupZS.



**Figure 2 Activity of intestinal myeloperoxidase.** Data are expressed as mean ± SD. a*P* < 0.05 *vs* groupSS and group SD, b*P* < 0.05 *vs* groupZS (8 animals per group at each time point).



**Figure 3** **Activity of superoxide dismutase and the content of malonaldehyde in rat intestine.** Data are expressed as mean ± SD. a*P* < 0.05 *vs* groupSS and group SD, b*P* < 0.05 *vs* group ZS(8 animals per group at each time point).



**Figure 4 Effect of dimethyl sulfoxide on intestinal mucosal blood flow.** Data are expressed as mean ± SD (8 animals per group at each time point).a *P* < 0.05 *vs* group SS and group SD; b*P* < 0.05 *vs* group ZS.

SS SD ZS ZD

|  |  |  |  |
| --- | --- | --- | --- |
| SD ZS ZDj | l | 33 | 18 |

**4 h**


**8 h**

|  |  |  |  |
| --- | --- | --- | --- |
| 9 | **snap13** | 4 | 29 |


**24 h**

|  |  |  |  |
| --- | --- | --- | --- |
| 19 | 22 | 62 | 2 |

**Figure 5 Intestinal histology.** dimethyl sulfoxide protected against intestinal injury following intraperitoneal injection of zymosan. Sections of the distal ileum were harvested at 4, 8 and 24 h after intraperitoneal injection of zymosan and stained with hematoxylin and eosin. All images were obtained at × 200 magnification with the black bar = 5 μm (8 animals per group).



**Figure 6 Gut injury scores.** Gut injury was scored by a pathologist blinded to the experimental groups on a scale of 0-4, (as described in Materials and Methods). a*P* < 0.05 *vs* groupSS andgroupSD, b*P* < 0.05 *vs* groupZS(8 animals per group at 4, 8 and 24 h after intraperitoneal injection of zymosan).



**Figure 7 Effect of dimethyl sulfoxide on diamine oxidase in plasma.** Blood samples and intestinal samples were obtained at 4, 8 and 24 h after intraperitoneal administration of zymosan. dimethyl sulfoxide protected the intestine from an increase in permeability. a*P* < 0.05 *vs* group SS and group SD, b*P* < 0.05 *vs* group ZS.

SS SD ZS ZD

**4 h**

|  |  |  |  |
| --- | --- | --- | --- |
| snap157 | snap5 | snap6 |  |

**8 h**

|  |  |  |  |
| --- | --- | --- | --- |
| **snap12** | 8d | snap11 |  |

**24 h**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | 4z | snap182 |

**Figure 8 Intestinal ZO-1 immunofluorescent staining at 4 h, 8 h and 24 h after injection of zymosan.** Animals in group ZS showed low fluorescent intensity at the cell periphery after intraperitoneal injection of zymosan, and dimethyl sulfoxide administration resulted in preservation of ZO-1 staining. All images were taken at × 400 magnification with the black bar = 5 μm (5 animals per group).

**4 h SS SD ZS ZD**


|  |  |  |  |
| --- | --- | --- | --- |
| **Series008_z0** | **Series006_z0** | **Series010_z0** | **Series014_z0** |

**8 h**

|  |  |  |  |
| --- | --- | --- | --- |
| **Series003_z0** | **Series003_z0** | **Series016_z0** | **Series008_z0** |

**24 h**

|  |  |  |  |
| --- | --- | --- | --- |
| **Series002_z0** | **Series006_z0** | **Series010_z0** | **Series006_z0** |



**Figure 9 Effect of dimethyl sulfoxide on the percentage of apoptotic intestinal cells by the TUNEL assay**. TUNEL stained paraffin sections from rats at 4, 8 and 24 h (original magnification, × 400). dimethyl sulfoxide inhibited intestinal cell apoptosis. a*P* < 0.05 *vs* group zD, b*P* < 0.05 *vs* group ZS.